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ABSTRACT
Purpose: The purpose of this study was to assess the feasibility and outcome of transvaginal ultra-
sound (US)-guided radiofrequency ablation of uterine fibroids assisted by a real-time virtual needle
tracking (VT) system.
Methods: Between January 2017 and February 2018, 19 patients (age 45±8 y, range 36–53 y) with 25
symptomatic uterine fibroids underwent transvaginal radiofrequency ablation (RFA) at a single center.
Mean number of fibroids for patient was 1.7 (min, max: 1–3). Patients with more than one fibroid were
10 (52.6%). Uterine fibroids (mean volume: 13.6mL; range: 5.3–41.9mL) were treated with a dedicated
internally cooled 17G 35 cm RF needle with 1 cm or variable active tip and the moving shot technique.
An electromagnetic system was used for showing a virtual needle during the procedure. Contrast-
enhanced ultrasound evaluation was performed before and immediately at the end of procedure.
Feasibility of the procedure, technical success rate, volume percentage reduction at 1, 3 and 6months,
clinical outcome (QOL score) and complications were analyzed.
Results: Procedure was feasible in 19/19 patients (100%). Technical success was achieved in 100% of
25 treated fibroids. Mean fibroids volume decreased from 13.6ml at baseline to 5.9ml at 6month
(reduction rate 62.7%, range 48.5–76.9; p< .05). No major immediate or late complications occurred.
Minor complications occurred in two patients. QOL score significantly improved from 68±36 at base-
line to 97±16 at six-months follow-up (p< .05).
Conclusion: Transvaginal US-guided RFA assisted by a real-time VT system is a feasible, safe and effect-
ive technique for the treatment of uterine fibroids.
ARTICLE HISTORY
Received 6 April 2018
Revised 15 May 2018
Accepted 18 May 2018
KEYWORDS
Uterine fibroid; transvaginal
myolysis; radiofrequency
ablation; virtual needle
tracking; minimally
invasive surgery
Introduction
Uterine fibroids are the most frequent pelvic benign solid
tumors in woman of reproductive age and the leading
benign indication for hysterectomy [1]. Fibroids have been
reported to occur at a rate of 2.0–9.2 per 1000 woman-years
and the incidence increases with age until menopause [2,3].
While often asymptomatic, fibroids can determine symp-
toms such as abnormal uterine bleeding, pelvic pressure,
pain, subfertility, dyspareunia and others [1]. Heavy menstrual
bleeding may be caused by submucous and intramural fib-
roids [4,5]; subserosal fibroids are more often asymptomatic
until they are sufficiently large so as to induce bulk symp-
toms. Transmural fibroids have submucous and subser-
osal components.
When symptomatic, uterine fibroids cause a significant
reduction in health-related quality of life (HRQOL) as deter-
mined by the uterine fibroid symptom and quality of life ques-
tionnaire (UFS-QOL), a validated fibroid-specific survey tool [6].
The traditional treatments for symptomatic fibroids are
represented by major surgery, such as hysterectomy and
myomectomy, both of which are associated with significant
complications and considerable morbidity [7]. Moreover, hys-
terectomy don’t preserve the uterus and fertility, so, in
woman who want future pregnancies or who wish to retain
their uterus for other reasons, the traditional surgical treat-
ment is myomectomy, which may be performed via laparot-
omy, laparoscopy, hysteroscopy or transvaginal, but it isn’t a
definitive therapy in many cases.
In the last years, some alternative minimally invasive treat-
ments have been proposed to treat symptomatic uterine fib-
roids in order to avoid major surgery and to preserve
potential fertility [8,9].
Uterine artery embolization (UAE) has been demonstrated
to be safe and effective on hypervascular fibroids [10], but
fertility-related issues are still debated [11]. Today, uterine
artery embolization is not recommended for women who
want to preserve fertility and fibroid recurrence is possible,
with approximately 20% of patients subsequently requiring
hysterectomy [12].
In the last decades, some new mini-invasive techniques
are adopted in the treatment of uterine fibroids and deter-
mine an improvement in woman’s quality of life. These
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procedures use various forms of energy to heat and ablate
uterine fibroids, include radiofrequency energy, focused ultra-
sound and microwaves [13–15].
Radiofrequency ablation (RFA) is a widespread modality to
achieve the local control of fibroids and creates a thermal fix-
ation and coagulation necrosis within fibroids that result in
reductions of volume, also reducing or eliminating symptoms
related to uterine fibroid.
Imaging guidance is very important for radiofrequency
(RF) electrode placement and procedure outcome is con-
nected to accurate probe placement and repositioning [16].
US guidance allows for accurate real-time visualization of the
RF electrode and is currently considered the main guidance
for such procedures [17,18]. However, uterine fibroids may
be located in challenging positions and gas bubbles released
during thermal ablation can reduce the visibility of the whole
procedure, increasing the risk of complications [19]. In this
setting, virtual needle tracking (VT) systems, which tracks the
position of the RF electrode through a small sensor on the
shaft, could be helpful in improving monitoring of the RF
electrode tip during ablation [17].
Finally, in some challenging cases, virtual tracking system
could be combined with fusion imaging, which enables ultra-
sound-guided ablation procedures enhanced by a ‘map’ fur-
nished by a superimposed diagnostic magnetic resonance
imaging (MRI) [20].
Virtual needle tracking has been described as a useful
guidance system for RF ablation of liver nodules [21] and for
RF ablation of benign thyroid nodules [22]; however, as far as
we know, it has never been used as guidance for RF ablation
procedures of uterine fibroids.
The purpose of this study was to assess the feasibility and
outcome of transvaginal ultrasound (US)-guided radiofre-
quency ablation of uterine fibroids assisted by a real-time vir-
tual needle tracking (VT) system.
Methods
Institutional review board approval was obtained. Informed
consent for RF ablation and to participate to our study was
obtained from all patients before each procedure. All patients
were informed on the potential risks and benefits of the RFA
and on the possible alternative surgical treatments.
Patients
Between January 2017 and February 2018, 19 premenopausal
women with 25 symptomatic uterine fibroids (diameter rang-
ing from 2.2–4.6 cm) underwent transvaginal US-guided RFA
assisted by a real-time VT system. The mean age± standard
deviation was (age 45 ± 8 y, range: 36–53 y). Full demograph-
ics data are reported in Table 1. A flow diagram of the study
is presented in Figure 1. The inclusion criteria were: 1) pres-
ence of symptomatic uterine fibroids; 2) refusal of hysterec-
tomy or myomectomy; 3) completion of childbearing and
4) biopsy proven benign fibroid. The exclusion criteria
were: 1) gynecological malignant pathology in the past
five years; 2) current pregnancy; 3) previous treatment with
gonadotropin-releasing hormone agonist and 4) uncontrolled
coagulation disorders.
Eighteen patients were symptomatic (89.5%): 10 women
complained menorrhagia (52.6%), eight patients presented
dysmenorrhea (42.1%), two pollakiuria (10.5%) and one dys-
pareunia (5.3%, Table 1).
Pre-treatment evaluation
Pre-treatment evaluation was performed in all patients with
conventional transabdominal ultrasound and transvaginal ultra-
sound (TV), using a high-end ultrasound machine (Logiq E9, GE
Healthcare, Milwaukee, WI), equipped with a 3–5MHz convex
probe and a 1–6MHz transvaginal probe. All evaluations were
performed within a week before treatment, to obtain a com-
plete pre-ablation assessment including the number, dimen-
sions and location of the uterine fibroids and to establish the
appropriate approach route for the RF electrode.
Contrast-enhanced ultrasound (CEUS) evaluation was also
performed in all patients after the intra-venous injection of
SonoVue micro-bubbles contrast (4.8ml; Bracco, Milan) to
evaluate the vascularity and to confirm the number of fib-
roids (Figure 2(A,B)), [23].
Immediately before ablation all patients underwent a US-
guided core-needle biopsy of all fibroids to be treated [24,25].
Procedure
Ablation technique was performed with intravenous moderate
sedation (induction with 1.0mg midazolam, 0.05ng fentanyl
and 1.5–2mg/kg propofol; maintenance with 100–200mg/kg/
min propofol) and prophylactic antibiotics were used during
the ablation. Women were placed in dorsal position, with empty
bladder and were monitored with electrocardiogram and pulse
oximeter. Standard sterile techniques and preparation were
adopted during the procedure.
All ablation procedures were performed by a physician
(G.T.) with more than 16 y of experience in interventional US.
Before ablation, transvaginal US was performed and VT
track system prepared. The VT system (VirtuTRAX, CIVCO
Medical Solutions, Coralville, IA) was used together with the
volume navigation system (V-Nav, LOGIQ E9, GE Healthcare,
Milwaukee, WI; Figure 2(C)). This platform has GPS tracking
Table 1. Patient’s characteristics at baseline.
Demographics
Patients (n) 19
Age, mean (min, max) 45 (36–53)
Fibroids
N. fibroids 25
N. for patient mean (min, max) 1.7 (1–3)
Patients with more than one fibroid, n (%) 10 (52.6%)
Disability
Disability, mean (min, max) 4.8 (0–10)
In patients with one fibroid 3.5 (0–10)
In patients with more than one fibroid 5.8 (5–10)
Symptoms
Symptomatic patients, n (%) 18 (89.5%)
Menorrhagia, n (%) 10 (52.6%)
Dysmenorrhea, n (%) 8 (42.1%)
Pollakiuria, n (%) 2 (10.5%)
Dyspareunia, n (%) 1 (5.3%)
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capability to generate a 3-D operating volume around the
patient. Two electromagnetic position sensors connected to
a position-sensing unit were attached to the probe (GE
Healthcare) through a bracket (Figure 2(A)). For RF electrode
tracking, a similar sensor was secured on the shaft of the 17-
gauge, 350-mm, fixed RF electrode (STARmed, Gyeonggi-Do,
Korea; Figures 2(B) and 4(A)). The 10-mm active tip was then
synchronized with the tracking device by a manual input of
the RF electrode length, thus locating the exact position of
the RF electrode and projecting its path on the US monitor
during the procedure. Therefore, the expected RF electrode
path is graphically superimposed on the B-mode image, with
the color of the line dependent on the orientation with the
imaging plane. When the expected RF electrode path lies
fully in the imaging plane (in-plane approach), a green line
appears on the B-mode scan depending on the angulation
and advancement of the RF electrode and its active tip is
located with a green V (Figure 4(B)). The path travelled by the
RF electrode is represented by a dashed line, whereas the pro-
spective RF electrode path is represented by a dotted line.
When the RF electrode is inserted with an out of plane
approach, the virtual path is projected and represented in red
or blue and the location where the RF electrode will intersect
the image plane is displayed in real time as a green circle. The
projection of the active tip on the US scan plane is marked as a
square, which becomes smaller as the RF electrode approaches
the US scan plane.
The ablation system included a RF generator (STARmed,
VIVA RF generator VRS01), an electric pump and the Cool-tip
RF electrode (STARmed Gyeonggi-Do, Korea). The electrode
was connected to the RF generator, which displays the tem-
perature of the electrode tip, the tissue impedance character-
istics, the ablation power and the time.
A 35 cm long 17G internally cooled electrode with an
exposed tip of 10mm or a variable exposed tip was used. A
dedicated needle guide attached to the transvaginal ultra-
sound probe was used to perform VT (Figure 3(A)). Once the
safest path to the target fibroid was identified with transvagi-
nal ultrasound, the electrode was appropriate placed into of
target fibroid under US real time guidance and VT. Ablation
was performed with fixed needle or with the ‘moving and
stepping shot’ technique [18], whereby the RF electrode is
inserted in the distal part of the nodule and then moved
10mm backward and upward in steps of 5–10 s.
The RF generator operated at 480 kHz with a maximum
power of 200W and at temperature ranging from 40 to 99 C
[26]. The time needed to obtain an appropriate volume of
coagulation depends on both temperature and tissue imped-
ance. The selected temperature to reach within the tissue
was 85 C and the RF generator automatically adjust the
power to maintain the selected temperature. To avoid a tem-
perature rise in the electrode, the carbonization of the sur-
rounding tissue and the increase of electrode impedance,
electrode cooling with a rapid flow ice water was used dur-
ing ablation.
Figure 1. Consort flow diagram of the study showing no patients dropout at six-months follow-up.
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During ablation, continuous transvaginal US was used to
monitor the procedure (Figure 4(B)). The total time of abla-
tion was determined based on increased echogenicity in the
fibroid. The target fibroid was ablated until the echo-
enhanced area by ablation reached 80–90% of the whole
fibroid. Five to ten minutes from the end of ablation CEUS
was performed in order to detect any eventual residual area
on enhancement (Figure 2(C,D)).
Postprocedural pain management was started on need
basis by administrating 2 g of paracetamol intravenously.
Figure 2. Contrast-enhanced ultrasound (CEUS) evaluation prior (A, B) and post (C, D) radiofrequency (RF) ablation of a submucosal fibroid (arrowheads). Note that
no residual contrast enhancement could be detected after ablation procedure (asterisk).
Figure 3. (A) Two small movable electromagnetic sensors are attached to the 1–6MHz transvaginal probe (TV) with a bracket. Then, the probe and the sensors are
covered with a sterile probe-cover and a sterile disposable needle-guide is applied. (B) 17-gauge, 350-mm, fixed radiofrequency (RF) electrode with electromagnetic
sensor secured on its shaft (C) low-field magnetic generator for volume navigation and virtual needle tracking.
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After the procedure the patients were monitored for
half day and then, if no complications were present, they
were discharged.
Variables and follow-up
Feasibility of the procedure, technical success rate, complica-
tions, volume percentage reduction and clinical outcome at
1, 3 and 6months were analyzed.
Feasibility of the procedure was defined as capability of
performing the treatment as preoperatively planned.
Technical success was defined as the treatment of the
fibroid according to predetermined protocol and was
assessed at postprocedural CEUS following the indications
of Ahmed et al. [27].
Complications were recorded and classified according to
Systemic inflammatory response syndrome criteria [28].
Volume of the fibroids was calculated through transvagi-
nal US using the formula of the ellipsoid (V¼ 4/3pH(height)W
(width)L(length)). Percentage volume reduction was calcu-
lated at sixmonths from treatment as follow: (initial volume
– final volume) x 100/initial volume.
Symptoms improvement at sixmonths was evaluated with
the uterine fibroids symptom (UFS) and quality of life (QOL)
questionnaire [6] with scores ranging from 0–100, were
higher QOL scores mean a better health-related QOL.
At the six-month follow-up, patients were also asked about
their overall satisfaction with the treatment, compared with
baseline, using a subjective semi-quantitative scale (poor, good
or excellent).
Statistical analysis
Anonymous data were entered into a database (Microsoft
Excel 2010, Redmond, WA) and then analysed with SPSS
Version 22.0 for Windows (IBM, Armonk, NY). Continuous vari-
ables were expressed as mean± SD, categorical variables
were displayed as frequencies.
Nodule volume at baseline was compared with that at the
six-month follow-up using the Wilcoxon test. A p value of .05
was considered to indicate significance.
UFS QOL scores were compared at different timepoints
with nonparametric methods (Kruskal-Wallis rank sum test).
A p value of .05 was considered to indicate significance.
Results
Transvaginal US-guided RFA assisted by a real-time VT system
was feasible in 19/19 patients (100%). Technical success was
achieved in all 25 fibroids (100%).
RF ablation procedures lasted between 16–43min
(mean time 28min) depending on the size and number of
treated fibroids.
Mean fibroids volume decreased from 13.6ml (range:
5.3–41.9ml) at baseline to 8.1ml at one month (reduction rate
40.4%, range 19.9–60.8; (p< .05)), to 6.9ml (reduction rate
49.3%, range 33.6–64.9; (p< .05)) and to 5.1ml at six month
(reduction rate 62.7%, range 48.5–76.9; p< .05; Table 2).
With volume reduction, we observed a significant symp-
tom reduction and mean QOL scores improvement at three
and six-months follow-up (p< .05), with a single patient com-
plaining persistent menorrhagia (5.3%; Table 2).
No major immediate or late complications such as pene-
trations/burn injuries of the bowel or bladder, sepsis or peri-
tonitis were reported. Minor complications, such as low fever,
lower abdominal pain and fluid in pelvic pouches on the US
examination, occurred in two patients: one patient presented
low fever and abdominal pain (5.3%), while another one
showed, on ultrasound evaluation, fluid in pelvic pouch
(5.3%). All this findings spontaneously resolved in the first
week after treatment.
Overall satisfaction at the six-month follow-up was rated
by patients as positive in 18 cases (89.5%). Excellent in 15/19
patients, good in 3/19 patients and poor in only one
case (5.3%).
Figure 4. (A) Positions of the operator and patient. (B) Display configuration with an in-plane approach. The prospective RF electrode path is represented by the
dotted line, whereas the dashed line represents the path travelled by the RF electrode. The RF electrode active tip is graphically displayed as a green ‘V’.
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Discussion
The results of our study confirm that RF ablation is an effect-
ive treatment modality for uterine fibroids. The VT system
was used successfully in all procedures, providing guidance
that allowed all procedures, even in challenging cases, to be
performed with a single puncture. At the six-month follow-
up, we observed a significant mean volume reduction and
clinical outcome improvement without any recurrence requir-
ing an additional RF ablation session.
These findings are also confirmed by a recent systematic
review of the literature [29] reporting high effectiveness of mini-
invasive uterine fibroids treatments. Moreover RF ablation
showed higher performances if compared to UAE [10] and also
a lower re-intervention rate compared to MRg-FUS [30].
The main innovation of the present study consists in the
application of a VT system to track the RF electrode during the
ablation session. This setting has great potential to provide
more accurate and radical RF ablation in several situations.
First, extreme precision is required when the RF electrode
active tip is obscured by the bubbles produced during the
ablation procedure as well as when the RF electrode active
tip is in the proximity of the fibroid margins, were multiple
fibroid punctures can cause serosal injury, adhesions and
potential myometrial disruption during a future pregnancy.
Therefore, the use of a virtual guidance is extremely helpful
for inexperienced operators, who may take advantage of the
more reliable localization of the RF electrode active tip, allowing
a shorter learning curve [31]. Moreover, when dealing with fib-
roids located in challenging positions, also ‘out-of-plane
approaches’, could be required; virtual needle guidance could
work-out the problem of the extremely poor visualization of the
RF electrode, so the fibroid can be reached and treated [22].
As previously described for the liver [21], we found some
technical problems that need to be solved to use this tech-
nique in the clinical setting. If the RF electrode is advanced
without bowing on the same path of the virtual tract, the tip
of the RF electrode coincides exactly with the target. When
dealing with hard fibroids, the RF electrode could bend con-
siderably, producing inaccuracies between the virtual tract
and the RF electrode and also increasing the risk of breaking
the Teflon coating of the electrode. This problem may be
solved using a RF electrode more rigid than those used in
this study and also moving gently inside the fibroid.
Moreover, we experienced some RF artefacts on the lower
part of the US image during RF ablation procedures.
Conversely, these RF artefacts do not influence the GPS-
enhanced VT system, which becomes extremely useful when
the native US image is not completely clear. However, this
problem needs to be solved by US manufacturers to enhance
the role of US guidance of RF ablation procedures.
No major complications occurred in our series, resulting in
a complication rate equal or lower to those reported in litera-
ture [32]. In this setting, we could speculate that the use of
virtual needle guidance could be helpful in reducing compli-
cations related to the poor visualization of the RF electrode
active tip, especially during ablation of fibroids closer to sen-
sitive structures.
Moreover, when dealing with submucosal fibroids, the
induction of artificial ascites with injection of a small amount
of saline solution (salinoma) [24] outside the uterine wall
could be helpful in order to reduce the risk of damage due
to heat to the surrounding bowel, vessels and bladder [33].
Good to excellent overall satisfaction was reported by a
majority of the patients who underwent the procedure. This
confirms that the procedure is positively accepted by
patients, because of the good results with better quality of
life, the preservation of uterus and fertility, short duration of
the procedure and rapid return to daily activities.
The main limitations of the present study are two. First,
the absence of a control group, as we meant to perform a
feasibility study, proving that the VT system could be useful
guidance for RF ablation of uterine fibroids.
The second limitation is the quite short follow-up; how-
ever, several articles have reported that a six-month follow-
up is sufficient to evaluate the outcome of the RF ablation
procedure [17,19]. On the other hand, other studies with very
long follow-up [34] suggest that incompletely treated nod-
ules may start to enlarge 1–2 y after ablation. Indeed, we
cannot be sure about the radicality of our treatment, but we
can speculate that a more confident and precise ablation
may be related to reduction of recurrences. Obviously, fur-
ther double-blind studies with longer follow-ups are required
to confirm this observation.
Conclusion
Image-guided percutaneous ablation appear to be effective
in obtaining volume reduction of uterine fibroids and in pro-
viding significant symptoms improvement. Moreover, this
technique was demonstrated to be effective also in the treat-
ment of several benign and malignant diseases around the
human body [35–38]. Thanks also to the wider application of
advanced techniques, such as CEUS [39–41] and virtual navi-
gation, with fusion imaging [20,42,43], US-guided RF myolysis
represent an effective alternative to conventional surgery for
the treatment of uterine fibroids. The VT system provides
effective guidance in RF ablation of uterine fibroids. Virtual
needle tracking system allows a safe and effective ablation of
uterine fibroids, allowing a constant view of the RF needle to
recognize the real tip despite ablation artifacts and reducing
complications. CEUS vascularity assessment helps to evaluate
Table 2. Longitudinal analysis (n¼ 25 fibroids).
Median at
baseline (IQR)
% Mean reduction (95% CI)
1 month 3 month 6 month
Volume (ml) 13.6 (5.3–41.9) 40.4% (19.9–60.8; p<.05) 49.3% (33.6–64.9) (p< .05) 62.7% (48.5–76.9) (p< .05)
Diameter (cm) 3.0 (2.2–4.6) 23.2% (12.9–33.7) 28.7% (20.0–37.4) 36.8% (28.7–45.0)
Clinical outcome
(UFS QOL score)
68 ± 36 70 ± 40 (NS) 84 ± 22 (p<.05) 97 ± 16 (p<.05)
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the technical success of the procedure and to highlight areas
of residual enhancement.
If confirmed by further prospective randomized trials, this
technique may improve the accuracy and outcome of RF
ablation while reducing the complication rate and shortening
the learning curve for this procedure.
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